Interleukin Genetics Announces Completion of Interim Financing

    WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 30, 2003--Interleukin
Genetics, Inc. (OTCBB:ILGN) announced today that it has completed an
additional $500,000 interim financing.
    This interim financing is in the form of a $500,000 promissory
note issued by Interleukin and sold to a consumer products company.
With this installment, Interleukin has received a total of $2.0
million from the same consumer products company. Interleukin now has
sufficient cash to meet its operating requirements through February
2003.

    ABOUT INTERLEUKIN GENETICS

    Interleukin Genetics is a biotechnology company focused on
inflammation. The company uses functional genomics to develop
diagnostic, therapeutic and nutraceutical products based on the
genetic variations in people to help prevent or treat diseases of
inflammation. Interleukin's TARxGET (Translating Advanced Research in
Genomics into more Effective Therapeutics) programs focus on the areas
of cardiovascular disease, rheumatoid arthritis and osteoporosis and
include the development of tests to assess a person's risk for heart
disease and osteoporosis as well as a test to help doctors and
patients choose the best course of therapy for rheumatoid arthritis.
These products will improve patient care and produce better allocation
of healthcare resources. In addition to its research partnerships with
numerous academic centers in the U.S. and Europe, Interleukin's
corporate collaborators include the leading healthcare organizations,
Kaiser Permanente and UnitedHealth Group. For more information about
Interleukin and its ongoing programs, please visit
http://www.ilgenetics.com.

    Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995) including statements regarding the
expectations about our future growth and operating results, our
ability to develop and commercialize our products, entering into one
or more strategic alliances on favorable terms with well-funded
partner, the expected benefits from any such strategic alliance, the
sufficiency of the proceeds from our interim financing to fund
operations through February 2003, and our efforts to obtain additional
financing through 2003. Because such statements include risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from those expressed
or implied by such forward-looking statements include, but are not
limited to, our ability to complete one or more strategic alliances,
raise necessary capital, complete clinical research and data analysis,
meet expectations about operating through February 2003 with the
proceeds from the interim financing, and meet clinical studies'
endpoints, risk of market acceptance of our products, risk of
technology and products obsolescence, delays in development of
products, reliance on partners, competitive risks and those risks and
uncertainties described in our Form 10-Q for the quarter ended
September, 2002, as filed on November, 2002, and in other filings we
have made with Securities and Exchange Commission. We disclaim any
obligation to update these forward-looking statements.


    CONTACT: Interleukin Genetics, Inc.
             Fenel Eloi, 781/398-0700